Abstract: Alpha-2 agonist-induced changes in packed cell volume (PCV), total solids (TS), selected biochemical parameters, and splenic thickness were investigated in horses. Four healthy mares were treated in a blinded, randomized, cross-over design with a dose of xylazine (0.5 mg/kg), romifidine (0.04 mg/kg), or detomidine (0.01 mg/kg) IV, and detomidine (0.02 mg/kg) IM. Hematology, TS, colloid osmotic pressure (COP), plasma osmolality; glucose, lactate, urea (BUN) and electrolyte concentrations; venous blood pH and ultrasonographic splenic thickness were evaluated at intervals for 300 min. Repeated measures analysis of variance (ANOVA) were performed with P < 0.05. There was a significant change over time in PCV and TS following each treatment (P < 0.001), with median (range) reductions of 20.9% (12.9% to 27.3%) and 5.8% (3.0% to 10.3%), respectively. Red blood cell count, BUN, and COP decreased while osmolality, glucose, Na(+), and splenic thickness increased. Treatments induced clinically significant transient changes in PCV, TS, and other biochemical parameters, which should be considered when assessing horses that received these drugs. Des changements induits à l’aide d’alpha-2 agonistes au niveau de la valeur d’hématocrite (VH), des solides totaux (ST), de paramètres biochimiques choisis et de l’épaisseur splénique ont été étudiés chez les chevaux. Quatre juments en santé ont été traitées dans une étude à l’aveugle, randomisée et croisée avec une dose de xylazine (0,5 mg/kg), de romifidine (0,04 mg/kg) ou de détomidine (0,01 mg/kg) IV et de détomidine (0,02 mg/kg) IM. L’hématologie, les ST, la pression osmotique colloïdale (POC), l’osmolalité plasmatique, le glucose, le lactate, l’urée (l’azote uréique du sang) et les concentrations d’électrolytes, le pH du sang veineux et l’épaisseur splénique échographique ont été évalués à des intervalles de 300 minutes. L’analyse de la variance des mesures répétées a été réalisée avec < 0,05. Il y avait des changements significatifs dans le temps de VH et des ST après chaque traitement ( < 0,001), avec des réductions moyennes (écart) de 20,9 % (de 12,9 % à 27,3 %) et de 5,8 % (de 3,0 % à 10,3 %), respectivement. Le nombre de globules rouges, l’azote uréique du sang et la POC ont diminué tandis que l’osmolalité, le glucose, Na et l’épaisseur splénique ont augmenté. Les traitements ont induit des changements transitoires significatifs sur le plan clinique dans la VH, les ST et les autres paramètres biochimiques qui devraient être considérés lors de l’évaluation des chevaux qui ont reçu ces médicaments.(Traduit par Isabelle Vallières).
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research investigates the impact of alpha-2 agonists (xylazine, romifidine, or detomidine) on the hematology, biochemistry, and splenic thickness in healthy horses.
Study Design
The research was conducted using a blind, randomized, cross-over design. This design ensures that the results are not influenced by any biases from the researchers or the experimental process.
The subjects of the research were four healthy mares that underwent treatment with either IV or IM-administered xylazine, romifidine, or detomidine.
Parameters Monitored
The researchers measured various parameters at 300-minute intervals. These parameters included hematology, total solids (TS), colloid osmotic pressure (COP), plasma osmolality, glucose, lactate, blood urea nitrogen (BUN), electrolyte concentrations, venous blood pH, and splenic thickness detected through ultrasonography.
Statistical Analysis
To evaluate the significance of the data collected, the researchers conducted a repeated measures analysis of variance (ANOVA) with a significance level of less than 0.05 (P < 0.05).
Study Outcomes
The study found significant changes in packed cell volume (PCV) and TS over time following each treatment, with median reductions of approximately 20.9% and 5.8%, respectively.
Red blood cell count, BUN, and COP decreased, while osmolality, glucose, sodium ion concentration (Na+), and splenic thickness increased.
The authors concluded that the therapies induced clinically significant transient changes in PCV, TS, and other biochemical parameters, suggesting that these effects should be taken into consideration while evaluating horses that have received these drugs.
Cite This Article
APA
Kullmann A, Sanz M, Fosgate GT, Saulez MN, Page PC, Rioja E.
(2014).
Effects of xylazine, romifidine, or detomidine on hematology, biochemistry, and splenic thickness in healthy horses.
Can Vet J, 55(4), 334-340.
Department of Companion Animal Clinical Studies (Kullmann, Sanz, Saulez, Page, Rioja) and Department of Production Animal Studies (Fosgate), University of Pretoria, Onderstepoort, South Africa.
Sanz, Macarena
Department of Companion Animal Clinical Studies (Kullmann, Sanz, Saulez, Page, Rioja) and Department of Production Animal Studies (Fosgate), University of Pretoria, Onderstepoort, South Africa.
Fosgate, Geoffrey T
Department of Companion Animal Clinical Studies (Kullmann, Sanz, Saulez, Page, Rioja) and Department of Production Animal Studies (Fosgate), University of Pretoria, Onderstepoort, South Africa.
Saulez, Montague N
Department of Companion Animal Clinical Studies (Kullmann, Sanz, Saulez, Page, Rioja) and Department of Production Animal Studies (Fosgate), University of Pretoria, Onderstepoort, South Africa.
Page, Patrick C
Department of Companion Animal Clinical Studies (Kullmann, Sanz, Saulez, Page, Rioja) and Department of Production Animal Studies (Fosgate), University of Pretoria, Onderstepoort, South Africa.
Rioja, Eva
Department of Companion Animal Clinical Studies (Kullmann, Sanz, Saulez, Page, Rioja) and Department of Production Animal Studies (Fosgate), University of Pretoria, Onderstepoort, South Africa.
Bassage LHI. Stabilizing the horse with surgical colic for referral. In: Robinson NE, Sprayberry KA, editors. Current Therapy in Equine Medicine. 6th ed. St Louis, Missouri: Saunders Elsevier; 2009. pp. 377–381.
Hodgson DS, Dunlop CI, Chapman PL, Smith JA. Cardiopulmonary effects of xylazine and acepromazine in pregnant cows in late gestation.. Am J Vet Res 2002 Dec;63(12):1695-9.
Hall LW, Clark KW, Trim CM. Anaesthesia in the horse. In: Hall LW, Clark KW, Trim CM, editors. Veterinary Anaesthesia. 10th ed. London, United Kingdom: Saunders; 2001. pp. 247–314.
Nel M, Lobetti RG, Keller N, Thompson PN. Prognostic value of blood lactate, blood glucose, and hematocrit in canine babesiosis.. J Vet Intern Med 2004 Jul-Aug;18(4):471-6.
Gasthuys F, Martens A, DeMoor A, Goossens L. Quantitative study of the diuresis induced by romifidine in the mare. Proc Assoc Vet Anaesth, J Vet Anaesth 1993:43. (Abstract).
Baldo CF, Garcia-Pereira FL, Nelson NC, Hauptman JG, Shih AC. Effects of anesthetic drugs on canine splenic volume determined via computed tomography.. Am J Vet Res 2012 Nov;73(11):1715-9.
Rizk A, Nocera I, Briganti A, Abouelnasr K, El-Khodery S, Tagawa M, Bonelli F. Dose-dependent effect of romifidine on intraocular pressure in clinically healthy buffalo (Bubalus bubalis). Heliyon 2019 Dec;5(12):e02930.
Hauschild G, Geburek F, Gosheger G, Eveslage M, Serrano D, Streitbürger A, Johannlükens S, Menzel D, Mischke R. Short term storage stability at room temperature of two different platelet-rich plasma preparations from equine donors and potential impact on growth factor concentrations. BMC Vet Res 2017 Jan 5;13(1):7.
Schaefer DMW, Videla R, Smith JS, Mulon PY, Flatland B, Zhu X. Hematology and clinical biochemistry reference intervals for companion pigs using the ADVIA 2120 and Cobas c501. PeerJ 2025;13:e18968.